Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 12/20 | 0.47 |
| ▸ | CES1 | P23141 | 7/20 | 0.47 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | PLA2G4C | Q9UP65 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7708913 | 0.94 | EPHX1 (0.48) | EPHX1FAAHCES1PLA2G4AALDH1A1 | |
| SCHEMBL1000784 | 0.86 | EPHX1 (0.42) | EPHX1FAAHCES1PLA2G4AALDH1A1 | |
| SCHEMBL1556843 | 0.82 | CNR1 (0.39) | MAPTBLMCYP1A2HSD17B10 | |
| SCHEMBL1556426 | 0.79 | EP300 (0.42) | FAAHMAPTBLMMEN1CYP1A2 | |
| SCHEMBL7716898 | 0.79 | EPHX1 (0.42) | EPHX1FAAHCES1ALDH1A1MAPT | |
| SCHEMBL10893304 | 0.78 | EP300 (0.45) | FAAHMAPTBLMMEN1CYP1A2 | |
| SCHEMBL10886696 | 0.78 | EP300 (0.45) | FAAHMAPTBLMMEN1CYP1A2 | |
| SCHEMBL10531391 | 0.78 | EP300 (0.45) | FAAHMAPTBLMMEN1CYP1A2 | |
| SCHEMBL1555372 | 0.76 | TSHR (0.41) | EPHX1BLMCYP1A2HSD17B10 | |
| SCHEMBL7045878 | 0.74 | EPHX1 (0.58) | EPHX1FAAHCES1PLA2G4AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178499-B1 | MATERIALS AND METHODS FOR DELIVERING COMPOSITIONS TO SELECTED TISSUES | UNIV CALIFORNIA (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11241380-B2 | Porous photonic crystals for drug delivery to the eye | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220000768-A9 | POROUS PHOTONIC CRYSTALS FOR DRUG DELIVERY TO THE EYE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-01-06 | — | — | US | disclosed |
| EP-3773730-A1 | DRUG DELIVERY FORMULATIONS | The Regents of The University of California (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210000744-A1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2019191132-A1 | DRUG DELIVERY FORMULATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190194358-A1 | Synthetic Antibodies | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-06-27 | — | — | US | disclosed |
| EP-3381446-A1 | POROUS PHOTONIC CRYSTALS FOR DRUG DELIVERY TO THE EYE | The Regents of The University of California (US) | 2018-10-03 | — | — | EP | disclosed |
| US-9937129-B2 | Materials and methods for delivering compositions to selected tissues | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-10 | — | — | US | disclosed |
| US-20180055765-A1 | POROUS PHOTONIC CRYSTALS FOR DRUG DELIVERY TO THE EYE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-03-01 | — | — | US | disclosed |
| EP-1212339-B1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008048970-A2 | SYNTHETIC ANTIBODIES | THE ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-1817003-A2 | POROUS PHOTONIC CRYSTALS FOR DRUG DELIVERY TO THE EYE | The Regents of the University of California (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006050221-A2 | POROUS PHOTONIC CRYSTALS FOR DRUG DELIVERY TO THE EYE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-1212339-A4 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1212339-A1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6369101-B1 | Therapeutic method to treat herpes virus infection | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2002-04-09 | — | — | US | disclosed |
| WO-2001014400-A1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-01 | — | — | WO | disclosed |
| US-6147200-A | NUCLEOSIDES FOR SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES HAVING INCREASED NUCLEASE RESISTANCE AND BETTER BINDING AFFINITY; DIAGNOSIS; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| WO-1998034603-A1 | USE OF BETULIN AND ANALOGS THEREOF TO TREAT HERPESVIRUS INFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000744-A1 | DRUG DELIVERY FORMULATIONS | PGR, FKBP1A, LPXN | EPHX1 4087/4885FAAH 3945/4885CES1 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.